A summary of the latest developments from 12 studies in BTK inhibition in B-cell malignancies presented at EHA2022.
Reading
8 Jul 2022
Reading
The Satellite Symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.
Video
22 Jun 2022
Oral presentation at EHA2022 describing the potential for combination therapy with a Bruton’s tyrosine kinase inhibitor (BTKi) and an anti-CD20 monoclonal antibody as a therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL).
Reading
26 May 2022
Exploring the potential for a BTK protein degrader as a therapeutic option in patients with B-cell malignancies.
Reading
26 May 2022
Poster presented at EHA2022 exploring the potential of PD-1 inhibition for relapsed/refractory (R/R) mature T- and NK-cell neoplasms.
Reading
26 May 2022
